BioCryst is profitable. Now it wants to buy more rare disease drugs
- Posted on August 28, 2026
- By CNBC
- 0 Views
- 1 min read
In brief
Generating AI summary…
BioCryst is profitable. Now it wants to buy more rare disease drugs
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
